BD to invest billions in U.S. manufacturing

BD (Becton, Dickinson and Co.) (NYSE: BDX) has reached an agreement with the Trump administration to invest billions of dollars in U.S. operations in exchange for tariff relief.

“This agreement reflects a shared commitment between the U.S. Government and BD to strengthening America’s healthcare infrastructure, expanding U.S. manufacturing capacity and supporting reliable access to essential medical technologies, ultimately building a more resilient healthcare system for the future,” BD CEO Tom Polen said in a news release posted today.

“The administration recognizes the importance of investing in a stronger, more secure healthcare supply chain, and BD is uniquely positioned to help bring that vision to life through our scale, innovation expertise and longstanding U.S. manufacturing footprint.”

President Trump first announced the agreement yesterday on Truth Social, Reuters reported.

Franklin Lakes, N.J.–based BD’s plans include:

Making $19 billion in U.S. capital, operational and supply chain investments over several years;
Using $3 billion of the overall investment to expand manufacturing at strategic production sites across the country;
Boosting end-to-end U.S. production by approximately 5 billion essential medical consumables annually, with BD’s share of domestically supplied essential medical consumables rising to roughly 80%;
U.S.-made steel will go into all BD needles used domestically.

In return, the Trump administration will provide BD with relief from future tariffs imposed under Section 232 on covered BD products and inputs. BD officials described the deal as providing greater long-term certainty for the company’s manufacturing and supply chain.

This is a BD aerial image of its major IV catheters manufacturing facility in Sandy, Utah, which the company said produces billions of molded components each year.

BD is celebrating the 70th birthday of its major IV catheters manufacturing facility in Sandy, Utah, which the company said produces billions of molded components each year. [Image courtesy of the company]

BD noted that it has been manufacturing in the U.S. for generations. When Jonas Salk announced plans to vaccinate more than 650,000 children with the polio vaccine in the 1950s, BD introduced its Hypak, the first sterile disposable glass syringe with a needle. Nearly 70 years later, BD boosted production of syringes and needles to support the COVID-19 vaccine.

BD has deep manufacturing roots in communities across the U.S.: Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Añasco, Pueto Rico; Sandy, Utah; El Paso, Texas; Covington, Georgia; and Sumter, South Carolina. It recently celebrated the 70th anniversary of its IV catheters plant in Sandy. Canaan, the largest syringe manufacturing operation in the United States, is marking 65 years.